Drug intelligence / Profile preview

RebmAb400

Development stage: Preclinical
Lead developer: Recepta Biopharma
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

RebmAb400 is a monoclonal antibody being developed by Recepta Biopharma, a Brazilian biotechnology company. It specifically targets the A34 antigen, a glycoprotein belonging to the family of adherens junction molecules. The A34 antigen is highly expressed in certain gastrointestinal cancers, particularly gastric and esophageal adenocarcinomas. RebmAb400 is currently in the preclinical or early development stage, with ongoing evaluations to define its therapeutic potential and clinical development path for cancer treatment.

Targets

VSIG1 (V-set and immunoglobulin domain-containing protein 1)

Beyond the preview

Go deeper on RebmAb400.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RebmAb400.

Explore the full profile